Statistically significant lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant improvements.
Meta analysis using the most serious outcome reported shows 18% [-156‑74%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials and higher quality studies. Early treatment shows efficacy while late treatment does not, consistent with expectations for an antiviral treatment.
Currently there is limited data, with only 31 control events for the most serious outcome in trials to date. Studies to date are from only 3 different groups.
Efficacy is variant dependent. mAb use may create new variants that spread globally1,2, and may be associated with prolonged viral loads, clinical deterioration, and immune escape2-5.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments are significantly more effective.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., Oct 2024, preprint, 1 author.